Saudi Al-Dawaa targets gene therapy local production

Sppemaco, the Saudi pharmaceutical company, aims to localize genetic and cellular medicines as part of its plans to increase production and develop advanced pharmaceutical industries. The company currently has an annual production capacity exceeding 3 billion units and intends to establish the first cellular and genetic medicine manufacturing unit at its facility in Qassim within 18 to 24 months, simultaneously securing the necessary approvals. Additionally, the company has signed an agreement with the Local Content Authority to localize the drug "Aflibercept," which is used to treat diabetic patients, with the goal of reducing its cost and making it available within Saudi Arabia. The company is also working on localizing active ingredients, cultivating biological medicines, and expanding its exports to 22 countries, with plans to extend into Africa and then Europe, in line with Saudi Vision 2030 to support the pharmaceutical sector and localize 40% of the pharmaceutical industries.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل